Microbiome, Cell & Gene Therapy

Microbiome: Zero to One
Microbiome, Cell & Gene Therapy · 10. August 2020
The microbiome is central to human health, and early-life gut microbiota has a profound implication on shaping our immune system, especially at the prenatal or neonatal stages. Since the discovery of the microbiome, many scientists have questioned both the mother-to-infant bacterial transmission process and microbiome evolution during the very first years of our lives. Is the prenatal or the postnatal period the most critical phase for the development of microbiota composition?
Cancer & Bacteria, a long story rising from the ashes
The interaction between cancer and bacteria is not new. As early as 1868, Busch began infecting sarcoma patients with erysipelas. This experiment was a semi-success in sofar as the reduction of the tumors was quickly followed by a reappearance of the cancer. In 1891, Coley pursued Busch's work and injected a throat cancer patient with Streptococcus erysipelas cultures: this time, the patient returned to a healthy condition for eight years.

An introduction to the Exosome world
“Huge opportunities”. “Many hurdles”. “Enormous potential”. It's just an excerpt of the several terms you'll come across if you search for them on the web. What am I talking about? Exosomes. Also referred to as Prostasomes, Tolerosomes, Dexosomes, or Nanovesicles. Markers of cancer diseases, the basis of broad diagnostic platform, and potential future therapeutics, exosomes have now surpassed 2,000 annual scientific publications. But why are exosomes so unique?
In Gut We Trust
Microbiome, Cell & Gene Therapy · 10. February 2020
Not a week goes by without a scientific article dealing with the microbiota. And we often hear that understanding the microbiota is explaining our illnesses. But what is exactly the microbiota and how does it influence our condition? An introduction to our inner forest or what is more commonly called our second brain...

The Dark Side Of CAR-T Therapy
Microbiome, Cell & Gene Therapy · 30. January 2020
The most common and potentially severe toxicity for bispecific antibodies and adoptive T-cell therapies (e.g. CAR-modified T-cell) is CRS.
SYnAbs one-stop-shop offer: complete CAR-VHH-T design and manufacturing for immunotherapy